A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2018
At a glance
- Drugs BMS-986299 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 30 Apr 2018 Planned End Date changed from 13 Dec 2021 to 19 Dec 2021.
- 02 Apr 2018 Planned End Date changed from 14 Nov 2021 to 13 Dec 2021.
- 02 Apr 2018 Status changed from not yet recruiting to recruiting.